3.連結財務諸表及び主な注記
(1)連結貸借対照表
| | (単位:千円) |
| 前連結会計年度 (2025年3月31日) | 当連結会計年度 (2026年3月31日) |
資産の部 | | |
流動資産 | | |
現金及び預金 | 833,883 | 2,089,338 |
売掛金 | 98,855 | 103,542 |
仕掛品 | 46,115 | 22,777 |
原材料及び貯蔵品 | 32,755 | 39,662 |
前渡金 | 28,820 | - |
その他 | 65,266 | 54,527 |
流動資産合計 | 1,105,697 | 2,309,848 |
固定資産 | | |
有形固定資産 | | |
建物 | 254,674 | 255,030 |
減価償却累計額及び減損損失累計額 | △254,674 | △255,030 |
建物(純額) | - | - |
機械及び装置 | 2,358 | 2,358 |
減価償却累計額及び減損損失累計額 | △2,358 | △2,358 |
機械及び装置(純額) | - | - |
工具、器具及び備品 | 992,128 | 1,052,694 |
減価償却累計額及び減損損失累計額 | △992,128 | △1,052,694 |
工具、器具及び備品(純額) | - | - |
有形固定資産合計 | - | - |
投資その他の資産 | | |
差入保証金 | 49,505 | 49,505 |
投資その他の資産合計 | 49,505 | 49,505 |
固定資産合計 | 49,505 | 49,505 |
資産合計 | 1,155,203 | 2,359,354 |
負債の部 | | |
流動負債 | | |
未払金 | 161,334 | 140,764 |
契約負債 | 142,054 | 12,106 |
未払法人税等 | 2,160 | 2,160 |
その他 | 22,189 | 14,936 |
流動負債合計 | 327,738 | 169,967 |
固定負債 | | |
長期未払金 | 51,067 | - |
資産除去債務 | 47,286 | 47,406 |
固定負債合計 | 98,353 | 47,406 |
負債合計 | 426,091 | 217,374 |
純資産の部 | | |
株主資本 | | |
資本金 | 50,000 | 50,000 |
資本剰余金 | 27,516,414 | 29,839,284 |
利益剰余金 | △26,908,248 | △27,818,886 |
自己株式 | △4 | △5 |
株主資本合計 | 658,161 | 2,070,392 |
新株予約権 | 70,950 | 71,588 |
純資産合計 | 729,111 | 2,141,980 |
負債純資産合計 | 1,155,203 | 2,359,354 |
E0536345640オンコセラピー・サイエンス株式会社OncoTherapy Science, Inc.通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2025-04-012026-03-31FY2026-03-312024-04-012025-03-312025-03-311falsefalsefalse456402024-03-31jppfs_cor:SubscriptionRightsToSharesMember456402026-05-08456402026-03-31456402025-04-012026-03-31456402025-03-31456402024-04-012025-03-31456402024-03-31456402026-03-31jppfs_cor:TreasuryStockMember456402025-04-012026-03-31jppfs_cor:TreasuryStockMember456402025-03-31jppfs_cor:TreasuryStockMember456402024-04-012025-03-31jppfs_cor:TreasuryStockMember456402024-03-31jppfs_cor:TreasuryStockMember456402026-03-31jpcrp_cor:ReportableSegmentsMember456402026-03-31tse-acedjpfr-45640:ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember456402026-03-31tse-acedjpfr-45640:CancerPrecisionMedicalBusinessReportableSegmentsMember456402025-04-012026-03-31jpcrp_cor:ReportableSegmentsMember456402025-04-012026-03-31tse-acedjpfr-45640:ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember456402025-04-012026-03-31tse-acedjpfr-45640:CancerPrecisionMedicalBusinessReportableSegmentsMember456402025-04-012026-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember456402025-03-31jpcrp_cor:ReportableSegmentsMember456402025-03-31tse-acedjpfr-45640:ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember456402025-03-31tse-acedjpfr-45640:CancerPrecisionMedicalBusinessReportableSegmentsMember456402024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember456402024-04-012025-03-31tse-acedjpfr-45640:ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember456402024-04-012025-03-31tse-acedjpfr-45640:CancerPrecisionMedicalBusinessReportableSegmentsMember456402024-04-012025-03-31jpcrp_cor:UnallocatedAmountsAndEliminationMember456402026-03-31jpcrp_cor:ReconcilingItemsMember456402025-04-012026-03-31jpcrp_cor:ReconcilingItemsMember456402025-03-31jpcrp_cor:ReconcilingItemsMember456402024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember456402024-03-31jppfs_cor:ShareholdersEquityMember456402024-03-31jppfs_cor:RetainedEarningsMember456402024-03-31jppfs_cor:CapitalSurplusMember456402024-03-31jppfs_cor:CapitalStockMember456402026-03-31jppfs_cor:SubscriptionRightsToSharesMember456402026-03-31jppfs_cor:ShareholdersEquityMember456402026-03-31jppfs_cor:RetainedEarningsMember456402026-03-31jppfs_cor:CapitalSurplusMember456402026-03-31jppfs_cor:CapitalStockMember456402025-04-012026-03-31jppfs_cor:SubscriptionRightsToSharesMember456402025-04-012026-03-31jppfs_cor:ShareholdersEquityMember456402025-04-012026-03-31jppfs_cor:RetainedEarningsMember456402025-04-012026-03-31jppfs_cor:CapitalSurplusMember456402025-04-012026-03-31jppfs_cor:CapitalStockMember456402025-03-31jppfs_cor:SubscriptionRightsToSharesMember456402025-03-31jppfs_cor:ShareholdersEquityMember456402025-03-31jppfs_cor:RetainedEarningsMember456402025-03-31jppfs_cor:CapitalSurplusMember456402025-03-31jppfs_cor:CapitalStockMember456402024-04-012025-03-31jppfs_cor:SubscriptionRightsToSharesMember456402024-04-012025-03-31jppfs_cor:ShareholdersEquityMember456402024-04-012025-03-31jppfs_cor:RetainedEarningsMember456402024-04-012025-03-31jppfs_cor:CapitalSurplusMember456402024-04-012025-03-31jppfs_cor:CapitalStockMemberxbrli:pureiso4217:JPY